Request a Kit

Fill out the form below to submit your order. The maximum amount of kits per order is 5 kits. US shipping only.

Still deciding which Guardant Complete products to order? Read the products’ overview or contact Client Services by phone at 855.698.8887855.698.8887 or email at

References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Palo Alto, CA. July 2021. 2. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed October 31, 2022. 3. National Cancer Institute. FDA approves blood tests that can help guide cancer treatment. October 15, 2020. 4. Guardant360 TissueNext Assay Specifications. Guardant Health, Inc. Palo Alto, CA. 5. Guardant360 TissueNext. National Library of Medicine. Bethesda, MD. 6. Guardant360® Assay Specifications. Guardant Health, Inc. Palo Alto, CA. 7. Guardant360. National Library of Medicine. Bethesda, MD. 8. Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2:1-13. doi:10.1200/PO.17.00286 9. Thompson JC, Carpenter EL, Silva BA, et al. Serial monitoring of circulating tumor DNA by next generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precis Oncol. 2021;5:510-524. doi:10.1200/PO.20.00321 10. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 11. Backgrounder: Guardant Reveal™ liquid biopsy test. Guardant Health, Inc. Palo Alto, CA. 12. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410 13. Janni W, Huober J, Braun T, et al. Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence. Poster presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; Philadelphia, PA. Accessed November 1, 2022. 14. Nagasaka M, Uddin MH, Al-Hallak MN, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20(1):82. doi:10.1186/s/12943-021-01371-1